Adaptimmune Therapeutics (ADAP) IPO Opens Up 13%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- US futures steady as oil retreats ahead of earnings deluge, Fed decision
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil slips but stays near six-month highs on Saudi attacks
- BofA flags further downside risk for stocks, yields and dollar
Adaptimmune Announces Pricing of Initial Public Offering
May 6, 2015 7:00 AM EDTOXFORD, United Kingdom and PHILADELPHIA, May 6, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP) today announced the pricing of its initial public offering of 11,250,000 American Depositary Shares (ADSs) at a price to the public of $17.00 per ADS. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,687,500 ADSs. The ADSs are expected to begin trading on the NASDAQ Global Select Market under the symbol "ADAP" on May 6, 2015. The offering is expected to close on May 11, 2015, subject to customary closing conditions. Adaptimmune estimates net proceeds from the offering will be approximately... More



